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discounted at 5% annually. Sensitivity analyses were performed. Results: Fenofibrate 
monotherapy improved mean quality-adjusted life expectancy by 0.09 QALYs versus 
placebo due to fenofibrate patients spending more time in mild DR states. Direct medi-
cal costs were AUD 898 higher for fenofibrate monotherapy, with additional treatment 
costs partially offset by reduced cost associated with advanced DR (e.g. ophthalmolo-
gist time and laser treatment), leading to an ICER of AUD 10,221 per QALY gained. 
Similarly, fenofibrate+statin led to an improvement of 0.05 QALYs versus statin alone 
with an incremental direct cost of AUD 1,707. The ICER for fenofibrate+statin was AUD 
33,350 per QALY gained versus statin alone. Sensitivity analysis showed that results 
were relatively insensitive to changes in a range of assumptions. ConClusions: The 
reduced risk of DR progression associated with fenofibrate treatment was projected 
to improve quality-adjusted life expectancy, with treatment costs partially offset by 
reduced costs of retinopathy care. ICERs indicated that fenofibrate therapy was in the 
range likely to be considered cost-effective in Australia.
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objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for the management of patients with type 1 (T1DM) and patients 
with type 2 (T2DM) diabetes. IDeg has demonstrated effective blood glucose con-
trol with less hypoglycaemic events and with an option for flexibility in dose time 
compared to insulin glargine (IGlar). The aim of this analysis was to evaluate the 
cost-effectiveness of IDeg versus IGlar in adults with T1DM in the UK. Methods: 
Meta-analysis data from two phase III clinical studies were used to populate a 
simple, transparent short-term model. The analysis was conducted from the UK 
National Health Service perspective and costs and benefits were calculated over 
a 12-month period. Sensitivity analyses were conducted to assess the degree of 
uncertainty around the results. In order to test the robustness of the results, two 
versions of the model were used. One applied disutilities derived from the SF-36 
questionnaire used in the clinical trials, the other applied disutilities associated with 
the occurrence of hypoglycaemic events. In both approaches an additional utility 
gain was attributed to the benefit of dosing flexibility. Baseline incidence of hypogly-
caemia was taken from a real-life study from the UK. Resource use associated with 
hypoglycaemia was documented in the clinical trials. Published tariffs were used 
as unit costs. Results: The base-case ICERs were £12,637/QALY and £13,349/QALY 
in the two modelling approaches, which are below commonly accepted thresholds 
for cost-effectiveness. The results were robust and largely insensitive to changes in 
input parameters. ConClusions: This short-term modelling approach allows the 
economic evaluation of newer insulin analogues when advanced long-term model-
ling based on HbA1c differences is inappropriate due to the treat-to-target nature of 
the clinical trials resulting in equivalent HbA1c levels. For patients in the UK with 
T1DM IDeg is a cost-effective treatment option compared with IGlar.
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objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for management of patients with type 1 (T1DM) and patients with 
type 2 (T2DM) diabetes. IDeg has demonstrated effective blood glucose control with 
less hypoglycaemic events and an option for flexibility in dose time compared to 
insulin glargine (IGlar). The aim of this analysis was to evaluate the cost-effec-
tiveness of IDeg versus IGlar in adults with T2DM initiating insulin therapy in the 
UK. Methods: Meta-analysis data from three clinical studies were used to populate 
a 1-year cost-utility model. The analysis was conducted from the UK National Health 
Service perspective. Sensitivity analyses were conducted to assess the robustness 
of results. Two versions of the model were tested, one applied disutilities derived 
from the SF-36 questionnaire used in the clinical trials, the other applied disutili-
ties associated with the occurrence of hypoglycaemic events. In both approaches 
an additional utility gain was attributed to the benefit of dosing flexibility. Baseline 
incidence of hypoglycaemia was derived from a UK real-life study. Resource use 
associated with hypoglycaemia was documented in the clinical studies. Official 
tariffs were used as unit costs. Results: Base-case ICERs were £15,705/QALY and 
£13,003/QALY in the two modelling approaches. Results were robust, with baseline 
rate of hypoglycaemia a key driver of results. Using hypoglycaemia rates from a 
subgroup of patients who experienced ≥ 1 hypoglycaemic event per year IDeg was 
highly cost-effective versus IGlar; with estimated ICERS of £4,706/QALY and £2,528/
QALY. ConClusions: This short-term modelling approach allows the economic 
evaluation of newer insulin analogues when advanced long-term modelling based 
on HbA1c differences is inappropriate due to treat-to-target trial design. For patients 
with T2DM on a basal-only insulin regimen, IDeg is cost-effective compared with 
IGlar and offers additional benefits to subgroups of patients, such as those suffering 
from recurrent hypoglycaemia.
PDB66
thE Cost-utility of insulin DEgluDEC ComParED with CurrEnt 
stanDarD of CarE in thE managEmEnt of tyPE onE anD tyPE two 
DiaBEtEs mEllitus in BElgium
Jugrin A.V.1, Lamotte M.1, Malfait M.2, Vandebrouck T.3
1IMS Health HEOR, Vilvoorde, Belgium, 2sa Novo Nordisk Pharma nv, Brussels, Belgium, 3Novo 
Nordisk Pharma, Brussels, Belgium
tively). ConClusions: Patients treated with CANA in dual therapy experienced an 
additional 0.21 QALYs over 40 years versus patients treated with GLIM. The primary 
drivers were improved weight while on agent and fewer hypoglycaemic events.
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objeCtives: In Poland, where long acting insulin analogues (LAA) are not currently 
reimbursed in T2DM, it is crucial to select a group of patients for whom LAA may 
be particularly preferred. Based on NICE recommendation such patients are those 
treated with human insulin (NPH) but not achieving glycaemic control. Thus the aim 
of this study was to evaluate the cost-effectiveness of insulin detemir (IDet) when 
compared to NPH in subpopulation of poorly controlled T2DM as defined by HbA1c 
≥ 8% and/or ≥ 1 episode of severe or nocturnal hypoglycemia recorded during ≥ 6 
months of NPH treatment. Methods: A validated computer simulation of diabetes 
model (IMS-CORE) was used to project long-term clinical and economic outcomes. 
Clinical effects in HbA1c improvement, BMI change and reduction in hypoglycemic 
episodes were modelled. Analysis was based on findings from the subgroups of the 
PREDICTIVE study – a real-world data trial – that closely reflects the defined target 
population. Two distinct insulin therapy regimens with IDet and NPH were evalu-
ated: basal-supported oral therapy (BOT) and a basal-bolus (BB) regimen. Baseline 
cohort characteristics, disease progression and utility estimates were obtained from 
systematic literature review. Costs were obtained from Polish published data. The 
analysis was conducted from a public payer and patient perspective over a lifetime 
time horizon. Discount rates were 5% (costs) and 3.5% (outcomes). Results: The 
mean QALY gain resulting from treatment initiation with IDet compared with NPH 
was 0,311 (BOT) and 0,451 (BB). Base-case incremental cost-effectiveness ratios 
(ICERs) were 38,136 PLN/QALY (9,113€ ) and 13,726 PLN/QALY (3,280€ ), respectively. 
At the current ICER threshold of 105,801 PLN/QALY (25,281€ ) in Poland, probability 
of IDet being cost-effective compared to NPH is 95% (BOT) and approaching 100% 
(BB). ConClusions: Based on generally accepted cost/QALY threshold values in 
the Polish settings, IDet was found to be a cost-effective option for T2DM patients 
with inadequately controlled diabetes.
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objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long duration 
of action for management of patients with type 1 (T1DM) and patients with type 
2 (T2DM) diabetes. IDeg have demonstrated efficacious blood glucose control with 
less hypoglycaemic events and with an option for flexibility in dose time compared 
insulin glargine (IGlar). The objective was to assess the cost-effectiveness of IDeg in 
Spain, compared with IGlar. The analysis focused on subgroups of patients within 
three treatment regimens: T1DM, T2DM treated with basal insulin in combination 
with oral anti-diabetics (BOT) and T2DM treated with basal-bolus (BB). Methods: 
A one-year cost-utility model driven by differences in hypoglycaemia was used. Two 
alternative utility approaches were used: in the first case, the utility gain was elicited 
from the clinical trials. In the second, published dis-utilities for hypoglycaemic 
events and self-monitoring blood glucose tests were used to calculate QALYs. Cost 
and utilities were also estimated for potential use of less blood glucose test strips. 
Three subgroups were analysed: those using twice daily IGlar, those with high risk 
of severe hypoglycaemia, and those obtaining extra utility from dosing flexibility. 
Unit costs pertained to public tariffs and reflected the payer perspective. Baseline 
incidence rates of hypoglycaemia and related resource use was derived from a 
Spanish observational study. Results: IDeg was dominant for T1DM, T2DM BOT 
and T2DM BB switching from twice daily. T2DM BOT with high risk of hypoglycaemia 
was also dominant. As for patients benefiting from dosing flexibility the cost/QALY 
were 6,921€ /QALY in T1DM, 9,244€ /QALY in T2DM BOT, and 33,099€ /QALY in T2DM 
BB. The use of the two different utility methods gave similar results. Univariate and 
probabilistic sensitivity analyses confirmed robust results. ConClusions: This 
analysis demonstrates that IDeg is a cost-effective option in Spain, when used in 
sub-groups of patients currently treated with long-acting insulin.
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objeCtives: Evidence from the landmark trials FIELD and ACCORD demonstrated 
that fenofibrate significantly reduces rates of diabetic retinopathy (DR) progression 
in type 2 diabetes patients (T2DM). This study evaluates the long-term cost-effective-
ness of fenofibrate mono- and combination therapy for DR in Australia. Methods: A 
seven-state Markov model simulated progression of DR based on data from the Blue 
Mountain Eye Study. Risk reductions for retinopathy progression were derived from 
FIELD for fenofibrate monotherapy (vs. placebo) and ACCORD for fenofibrate+statin 
(vs. statin alone). No additional benefits were assumed beyond 5 years (DR progression 
was the same with/without fenofibrate after year 5). Quality-adjusted life expectancy, 
direct costs and incremental cost-effectiveness ratios (ICERs) were reported over 10 
years. Unit costs (2012 Australian dollars, AUD), resource use and utilities were taken 
from country-specific sources/expert opinion. Future costs and clinical benefits were 
